COMIRNATY CLINICAL TRIAL
July 27, 2020 - October 29, 2020

	Comirnaty	Placebo	Absolute/Relative Effectiveness
Group size	22,030	22,030	
Severe Adverse Events	264 1.20%	154 0.70%	-71% -0.50%
Cases (with prior infection)	2 0.01%	7 0.03%	71% 0.02%
Severe Cases	1 0.00%	30 0.14%	97% 0.13%
Deaths	15 0.07%	14 0.06%	-7% 0.00%
Severe Adverse Events / Severe Cases	14x		
Severe Adverse Events / Cases (with prior infection)	47x		

https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full-text
https://www.nejm.org/doi/full/10.1056/nejmoa2034577

Delta-variant SARS-CoV2 breakthrough infections following vaccination BNY162b2
“infectiousness protection starts diminishing for patients two months post vaccination and ultimately vanishes for patients 6 months or longer post vaccination.”
https://www.medrxiv.org/content/10.1101/2021.08.29.21262798v1

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
“Conclusions These results indicate a strong effect of waning immunity in all age groups after six months.”
https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1

Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger...
“Collectively, these findings suggest that the established two-dose vaccination regimen elicits less durable immune responses in the elderly compared to young adults.”
https://www.medrxiv.org/content/10.1101/2021.08.26.21262468v1

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
https://pubmed.ncbi.nlm.nih.gov/16115318/

Emerging Evidence Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
“Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity
This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity."
https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1